{"pmid":32286538,"title":"Human antibodies can neutralize SARS-CoV-2.","text":["Human antibodies can neutralize SARS-CoV-2.","Nat Rev Immunol","Catalan-Dibene, Jovani","32286538"],"journal":"Nat Rev Immunol","authors":["Catalan-Dibene, Jovani"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286538","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41577-020-0313-6","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664071627202101248,"score":8.233237,"similar":[{"pmid":32249063,"title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","text":["Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.","Trends Immunol","Jiang, Shibo","Hillyer, Christopher","Du, Lanying","32249063"],"abstract":["Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs."],"journal":"Trends Immunol","authors":["Jiang, Shibo","Hillyer, Christopher","Du, Lanying"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249063","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.it.2020.03.007","keywords":["MERS-CoV","SARS-CoV","SARS-CoV-2","human coronaviruses","neutralizing antibodies"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136198520832,"score":51.823566}]}